Yuhan Corporation Receives KRW 43.2 Billion Milestone Royalty for 'Rayzertinib'

[Asia Economy Reporter Kum Boryeong] Yuhan Corporation announced on the 8th that it is expected to receive a technology fee of 35 million USD (approximately 43.2 billion KRW) following the achievement of milestone payments for the EGFR-targeted anticancer drug 'Lazertinib,' which was licensed out to Janssen Biotech, Inc.

This amount corresponds to more than 2.5% of Yuhan Corporation's consolidated equity capital.